

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study

Julie Helms ^{1,2}, Charles Tacquard ³, François Severac ⁴, Ian Leonard-Lorant ⁵, Mickaël Ohana ⁵, Xavier Delabranche ³, Hamid Merdji ^{1,6}, Raphaël Clere-Jehl ^{1,2}, Malika Schenck ⁷, Florence Fagot Gandet ⁷, Samira Fafi-Kremer ^{2,8}, Vincent Castelain ⁷, Francis Schneider ⁷, Lélia Grunebaum ⁹, Eduardo Anglés-Cano ¹⁰, Laurent Sattler ⁹, Paul-Michel Mertes ³, Ferhat Meziani ^{1,6}, and for the CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis)

This article has undergone peer-review and has been accepted for publication in the Journal Intensive Care Medicine (ICM). This is not yet the definitive version of the manuscript as it will undergo copyediting and typesetting before it is published in its final form with a DOI.

DOI: 10.1007/s00134-020-06062-x

¹ Hôpitaux universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, Strasbourg, France

² ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Strasbourg, France

³ Hôpitaux universitaires de Strasbourg, Service d'Anesthésie-Réanimation, Nouvel Hôpital Civil, Strasbourg, France

⁴ Hôpitaux universitaires de Strasbourg, Groupe Méthodes en Recherche Clinique (GMRC), Hôpital Civil, Strasbourg, France

⁵ Radiology Department, Nouvel Hôpital Civil, Strasbourg University Hospital

⁶ INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France

⁷ Hôpitaux universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Hautepierre, Strasbourg, France

⁸ Hôpitaux universitaires de Strasbourg, Laboratoire de Virologie Médicale, Strasbourg, France

⁹ Hôpitaux universitaires de Strasbourg, Laboratoire de d'Hématologie, Hautepierre, Strasbourg, France

¹⁰ Université de Paris, Innovative Therapies in Haemostasis, INSERM UMR_S 1140, F-75006 Paris, France.

Correspondence to:

Ferhat Meziani (MD, PhD)

Service de Médecine Intensive Réanimation – Nouvel Hôpital Civil - 1, place de l'Hôpital
F-67091 STRASBOURG cedex (France)

Abstract:

Purpose: Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of COVID-19 infection.

Methods: All patients referred to 4 intensive care units (ICUs) from two centers of a French tertiary hospital for acute respiratory distress syndrome (ARDS) due to COVID-19 between March 3rd and 31st 2020 were included. Medical history, symptoms, biological data and imaging were prospectively collected. Propensity score matching was performed to analyze the occurrence of thromboembolic events between non- COVID-19 ARDS and COVID-19 ARDS patients.

Results: 150 COVID-19 patients were included (122 men, median age 63 [53;71] years old, SAPSII 49 [37;64] points). Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%). 28/29 patients (96.6%) receiving continuous renal replacement therapy experienced circuit clotting. Three thrombotic occlusions (in 2 patients) of centrifugal pump occurred in 12 patients (8%) supported by ECMO. Most patients (>95%) had elevated D-dimer and fibrinogen. No patient developed disseminated intravascular coagulation. Von Willebrand (vWF) activity, vWF antigen and FVIII were considerably increased and 50/57 tested patients (87.7%) had positive lupus anticoagulant. Comparison with non-COVID-19 ARDS patients (n=145) confirmed that COVID-19 ARDS patients (n=77) developed significantly more thrombotic complications, mainly pulmonary embolisms (11.7 versus 2.1%, p<0.008). Coagulation parameters significantly differed between the two groups.

Conclusion: Despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications. Higher anticoagulation targets than in usual critically ill patients should therefore probably be suggested.

Keywords: COVID-19, ARDS, thrombosis, lupus anticoagulant, coagulopathy

Take-home message:

- In a prospective cohort study, we have shown that sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients with COVID-19 ARDS during their ICU stay, mainly pulmonary embolisms (25 patients, 16.7%).
- Despite anticoagulation, a high number of patients with COVID-19 ARDS developed life-threatening thrombotic complications, meaning that higher anticoagulation targets than in usual critically ill patients should probably be considered.

Introduction

Patients with severe acute respiratory syndrome (SARS-CoV-2), also known as coronavirus disease 2019 [COVID-19], who are admitted on intensive care units (ICUs) mainly develop respiratory and digestive symptoms [1, 2]. However, some patients may also develop coagulopathy, then associated with poor prognosis [3]. In a retrospective series of 183 consecutive patients, Tang et al. reported that 71.4% of non-survivors met the criteria of disseminated intravascular coagulation (DIC) while only 0.6% of survivors did. In 99 Chinese patients, Chen et al. [4] also reported abnormal “coagulation function”, including increased D-dimers in 36 patients (36%), decreased prothrombin time (PT) in 30 patients (30%), or increased activated partial thromboplastin time (aPTT) in 16 patients (16%). Similarly, among 13 patients admitted in ICU, Wang et al. [5] reported that prothrombin time and D-dimer level on admission were significantly higher in ICU patients than non-ICU patients. As is the case with sepsis, prophylactic anticoagulation of patients with severe COVID-19 may be recommended [6]. Recent recommendations on coagulopathy management, based on the follow-up of standard coagulation markers (D-dimers, prothrombin time, fibrinogen, and platelet count), have been put forward by the International Society of Thrombosis and Haemostasis (ISTH) [7]. In another retrospective study stratifying patients based on sepsis-induced coagulopathy (SIC) score or D-dimer level, Tang et al. [8] suggested that heparin would decrease mortality in severe COVID-19 patients who met the SIC criteria or have markedly elevated D-dimers.

Despite increasing evidence of coagulation disorders, based on these retrospective data in a small number of patients, no data are available for the most severe patients, i.e. those admitted in ICU. In addition, none of the published articles describe the clinical or radiological issues related with these coagulation disorders [3-5]. The clinical relevance of these results may still be questionable.

On the basis of a comprehensive clinical examination, backed with biological and radiological data of a homogeneous prospective cohort of critically ill patients with acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 infection, admitted to 4 intensive care units (ICUs) in two centers of a French tertiary hospital, we have aimed at describing the COVID-19-induced thrombotic complications and comparing them with non-COVID-19 ARDS patients.

Patients and Methods

Patients

Between March 3rd and March 31st 2020, all patients referred for ARDS [9] due to SARS-CoV-2 were prospectively included on admission in four intensive care units (ICUs) in two centers of a French tertiary hospital. There was no exclusion criterion. Patients were managed following current guidelines [6] without specific therapeutic intervention. Approval was obtained from the local ethics committee of the University Hospital of Strasbourg (reference CE-2020-34). This study encompasses all demographic characteristics, medical history, clinical signs, biological and imaging data. Data were analyzed on April the 7th, which means at least 7 days of follow-up for the most recent patients.

A historical prospective cohort of “non-COVID-19 ARDS” patients (NCT #02391792) included between 2014 and 2019 was used for the comparison of COVID-19 ARDS to non- COVID-19 ARDS. All the patients had a bacterial or viral ARDS defined according to Berlin definition [9]. Their characteristics are summarized in table 1.

Outcomes

The primary end-point was to compare the occurrence of any thrombotic event (deep vein thrombosis, pulmonary embolism, myocardial infarction, mesenteric ischemia, lower limb ischemia, cerebral ischemic attack) between patients with COVID-19 ARDS and patients with non-COVID-19 ARDS. The secondary endpoints were to compare: the occurrence of each of the aforementioned thrombotic complications, the occurrence of RRT filter coagulation, the median lifespan of each RRT circuit, the occurrence of ECMO oxygenator coagulation, the occurrence of hemorrhagic complications and the results of coagulation tests.

Laboratory analysis

Platelet count and coagulation tests were performed daily during the ICU stay, including prothrombin time (PT), antithrombin activity (AT), fibrinogen, D-dimers and activated partial thromboplastin time (aPTT) in order to perform DIC scores. Factor V (FV), von Willebrand factor (vWF) antigen, vWF activity, and factor VIII (FVIII) activity were performed. Lupus anticoagulant was searched when a coagulation disorder was suspected, based on a prolonged aPTT at ICU admission or on the occurrence of a thrombotic event during ICU stay. Please refer to supplementary material for further details.

DIC scoring systems

The JAAM-DIC 2016 score [10], ISTH overt-DIC score [11] and SIC score [8] were calculated daily until day 7. Scores were considered positive as commonly accepted, if ISTH overt-DIC was 5 points or more, JAAM-DIC score was 4 points or more and if SIC was 4 points or more.

Imaging

Patients with suspected pulmonary embolism, based on their clinical (worse PaO₂/FiO₂ despite inhaled nitric oxide or after prone positioning or hemodynamic impairment requiring fluid challenge and/or increased norepinephrine infusion rate, dilated right ventricle – even without acute cor pulmonale) or laboratory parameters evolution (a rapid elevation of D-dimer despite anticoagulation), had a CT pulmonary angiography (CTPA) done, either at the admission in ICU or during their stay. All CTPA

were acquired on 64+ row scanners, after injection of 50 to 75 mL of high concentration iodine contrast media, with the use of a bolus-tracking technique and a threshold of 160HU to 250HU in the main pulmonary artery. When established, pulmonary embolism was classified as truncular, lobar, segmental or sub-segmental, based on the location of the most proximal luminal defect.

Patients with suspected peripheral arterial ischemia were explored with CT angiography (CTA). Lower-limb CTA were acquired on 64+ row machines, with arterial phase after injecting 100mL of high concentration iodine contrast media.

Patients with suspected mesenteric ischemia, based on clinical presentation and/or biological abnormalities, had a contrast-enhanced chest abdomen and pelvis CT (CAP CT). All CAP CT were acquired on 64+ row machines, with mandatory unenhanced, arterial and venous abdomino-pelvic phases, after injecting 100 mL of high concentration iodine contrast media.

Patients with suspicion of stroke, based on pathological neurological examination, had either a non-contrast brain CT and/or a brain MRI with diffusion weighted imaging and 3D FLAIR acquisitions.

All CT and MR examinations were read by consultant radiologists specialized in emergency radiology.

Statistic

Continuous variables are presented as median with the first and third quartile and were compared using non parametric Wilcoxon tests. Categorical variables are presented as numbers and proportions and were compared using Pearson's χ^2 tests or Fisher's exact tests. In order to compare the outcomes in this observational study, a propensity score analysis was performed. Propensity scores was generated using a multivariable logistic regression model with the group (non-COVID-19 ARDS or COVID-19 ARDS) as the dependent variable and baseline characteristics that were unbalanced between groups or had clinical relevance as the independent variables (age, sex, medical history of malignancies, cardiovascular diseases, cerebrovascular diseases, venous thrombo-embolic event, immune diseases, chronic liver diseases, chronic renal diseases, respiratory diseases, SAPS II, SOFA, PaO₂/FiO₂ on ICU admission, anticoagulant treatment and ECMO). The COVID-19 and non-COVID-19 patients were then paired 1:3 on these propensity scores with a caliper size of 0.1 x logit [SD of the propensity score]. In order to take into account the matching, variables were then compared using GEE (generalized estimating equation) models with an unstructured covariance matrix. Binomial distribution was used for binary variables and Gamma distribution was used for continuous variable. Goodness of fit for Gamma distribution was assessed using histograms and quantiles plots. Sensitivity analysis were performed using multivariable logistic regression models on the whole population. Results are presented as odds ratio with 95% confidence intervals. A p-value < 0.05 was considered as statistically significant. All the analyses were performed using R software version 3.6.0. R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.

Results

Baseline Characteristics of the Patients

One hundred and fifty consecutive patients, with positive real-time reverse transcriptase PCR tests for COVID-19, admitted in 4 participating ICUs were included in the study. Median age was 63 [53; 71] years old and the male-to-female ratio was 122/28 (81.3% of men). The median of simplified acute physiology score (SAPS) II was 49 [37; 64] points. The median length of stay in ICU was 9.6 ± 4.2 days and mortality rate was 8.7%, considering that 101 patients (67.3%) were still intubated at the time of data analysis. Thirty-six patients had been discharged from ICU by time of data analysis. Eighty-four patients (60.0%) received lopinavir + ritonavir, 8 (5.3%) remdesivir, 49 (32.7%) hydroxychloroquine and 9 (7.5%) did not received any antiviral treatment. Medical history, patient characteristics, thrombotic/ischemic and hemorrhagic complications during ICU stay of both COVID-19 and non-COVID-19 patients are summarized in Table 1.

Thrombotic and ischemic complications

Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients during their ICU stay, mainly pulmonary embolisms. One hundred CTPA were performed in 99 patients to investigate the cause of a respiratory re-aggravation or because of a significant increase of D-dimers. Twenty-five (25%) showed pulmonary embolisms (24 men, mean age 62 years old): 9 troncular, 8 lobar, 5 segmental and 3 subsegmental pulmonary embolisms. Pulmonary embolism was diagnosed in median 5.5 [2.8; 9.3] days after ICU admission.

Fifteen brain CT and 10 brain MRI were performed in 25 patients because of pathological neurological examinations, and 4 showed hemorrhagic complications or ischemic strokes. Two CT were performed in a context of recent head trauma after a fall, but none showed sign of ischemic stroke. In one patient, there was a complete occlusion of the right internal carotid artery, possibly preexisting to COVID-19 infection, without any sign of ischemic stroke.

Two patients had a left cerebellar ischemic stroke in MRI, which was acute in one case with hyperintensity on diffusion weighted imaging and decreased diffusion coefficient and probably preexisting to COVID-19 infection in the other case because of ADC increase, lack of contrast enhancement and absence of mass effect; the third patient has bilateral multiple periventricular ischemic lesions. The last one had an acute voluminous fronto-temporal intra-parenchymatous hematoma and multiple recent ischemic lesions.

Twenty-eight patients out of 29 (96.6%) receiving continuous renal replacement therapy (RRT) experienced circuit clotting. The median lifespan of an RRT circuit was 1.5 [1.0; 2.0] days, compared to the 3 days recommended by the manufacturer, and the total number of circuits was used 141 circuits for 230 days of continuous RRT (4.9 devices/patient).

Twelve patients (8%) were supported by extracorporeal membrane oxygenation (ECMO), 11 with venovenous ECMO because of respiratory failure, and 1 patient with veno-arterial ECMO because of respiratory failure complicated with cardiogenic shock due to pulmonary embolism.

We identified 3 thrombotic occlusions of centrifugal pump in 2 patients, needing its prompt replacement after a runtime of 5 days in the first patient and 4 and 7 days in the second one.

No patients suffered from a myocardial infarction during the ICU stay, although a high number of the patients (48%) suffered from cardiovascular comorbidities. A 62-year-old patient, without any cardiovascular medical history except smoking cessation for over 20 years and dyslipidemia, developed an acute limb ischemia. His medical history showed no obliterating arteriopathy of the lower limbs, he did not receive catecholamines and no atrial fibrillation was reported during his stay. A segmental pulmonary embolism was also diagnosed on a CTPA performed the same day because of persistent hypoxemia.

Mesenteric ischemia was suspected in 5 patients, with positive CAP CT in one case (30 cm of non-enhancing bowel).

No patient suffered from digital/toes necrosis or purpura.

The antiviral therapy item was not associated to thrombogenic tendencies (data not shown).

Hemorrhagic complications

Only 4 patients (2.7%) presented hemorrhagic complications. Patients 1 and 2 had recent head trauma before ICU admission; the first one was diagnosed with an intra-axial hematoma; the second one with a diffuse intra and extra-axial hemorrhagic lesions. The third patient had an intra-parenchymatous hematoma (described above). The fourth patient developed hemorrhagic complications due to ECMO, with a voluminous hematoma at the insertion site of the cannula (scarpa) requiring the hematoma removal and local coagulation.

Coagulation disorders

At baseline, most patients (>95%) had elevated D-dimer and fibrinogen levels. Platelets, prothrombin time, aPTT and antithrombin remained within normal ranges in 120 (80.0%), 108 (72.0%), and 100 patients (66.7%) respectively, which explains the normal JAAM-DIC (<4 points) in 144 patients (96.0%) and normal ISTH (<5 points) scores in all patients. Median scores were 0 [0; 1] and 2 [2; 3] points for JAAM-DIC and ISTH scores respectively. Only 6 patients (2.7%) had a positive JAAM-DIC score and none had a positive ISTH score. Even the SIC score, which detects patients “at risk of developing DIC”, was positive in only 22 patients (14.7%).

Von Willebrand factor (vWF) activity and vWF antigen (vWF:Ag) were considerably increased, as well as factor VIII. Furthermore, 50 patients out of the 57 tested (87.7%) had positive lupus circulating anticoagulant during their ICU stay (table 2).

There was no heparin-induced thrombocytopenia in the 4 patients in whom it was searched because the clinical or biological data might have been compatible with this diagnosis.

Comparing COVID-19 ARDS with non-COVID-19 ARDS patients

Seventy-seven patients with COVID-19 ARDS or 145 patients with non-COVID-19 ARDS were matched. Thirty-five COVID-19 patients were matched with 1 non-COVID-19 patient, 16 COVID-19 patients with 2 non-COVID-19 patients et 26 COVID-19 patients with 3 non-COVID-19 patients. Characteristics of both COVID-19 and non-COVID-19 patients are summarized in table 1 and their outcomes in table 3. The sex, age, medical history, organ failures and severity score (Sepsis-related Organ Failure Assessment - SOFA, SAPS II), PaO₂/FiO₂ ratio, anticoagulant treatment at baseline and ECMO support after matching were not different between groups (table1).

As assessed after matching, more thrombotic complications were diagnosed in COVID-19 ARDS patients than in patients with non-COVID-19 ARDS (9 patients (11.7%) versus 7 patients (4.8%), OR 2.6 [1.1 - 6.1], $p=0.035$), with significantly more pulmonary embolisms (9 patients (11.7%) versus 3 patients (2.1%), OR 6.2 [1.6 - 23.4], $p=0.008$).

The total number of RRT circuits per dialyzed patient was higher in COVID-19 patients and their median lifespan shorter (table 3).

Coagulation parameters also differed between the two groups (Fig. 2): prothrombin time, antithrombin, fibrinogen and platelets were significantly higher in COVID-19 patients compared to non-COVID-19 ARDS patients; aPTT and D-dimers were significantly lower in COVID-19 patients.

Sensitivity analyses were performed to compare the occurrence of thromboembolic complications and pulmonary embolism on the whole population using multivariable logistic regression models incorporating covariates used to construct the propensity score. The adjusted odds ratios were similar to those calculated with propensity score analysis for both events (OR = 2.7 [1.1 - 6.6], $p = 0.028$ for thromboembolic complications and OR = 9.3 [2.2 - 40.0], $p = 0.003$ for pulmonary embolism).

Discussion

In a prospective cohort, we have evidenced the high prevalence of clinically relevant thrombosis, essentially pulmonary embolisms (16.7%), in COVID-19 patients admitted in ICU for hypoxemic acute respiratory failure. These thrombotic complications occurred despite prophylactic or therapeutic anticoagulation.

A systemic inflammatory response syndrome, assessed by high fibrinogen, was present in all patients and was responsible for activation of blood coagulation in almost all COVID-19 patients, as demonstrated by progressive D-dimers elevation. However, the coagulation activation pattern was not the same as in our cohort of non-COVID-19 ARDS patients. It was not the same either as in septic shock without DIC: D-dimers levels were less elevated (2.27 mg/L vs. 4.30), PT, aPTT and AT were within normal ranges and fibrinogen was higher (7.0 g/L vs. 5.6) [12]. Interestingly, while 30 to 40% of septic shock patients develop DIC [13], no COVID-19 patient was diagnosed with DIC using ISTH “overt” score and only 6 with JAAM-DIC score. Even the SIC score, which should detect patients at risk of developing DIC was positive in only 22 patients.

We can therefore reasonably assume that the mechanisms leading to DIC differ in COVID-19 patients from those usually described in ICU patients. Then, the mechanisms leading to localized thrombosis (PE, stroke or mesenteric infarct) or to circuit device (either RRT or ECMO) thrombosis may not be the same either. Indeed, RRT circuit thrombosis, despite systemic anticoagulation by continuous infusion of heparin and/or citrate [14], may be explained by both the very high level of fibrinogen and the ultrafiltration resulting in higher concentrations inside the dialyzer capillaries, rather than by contact phase activation by the circuit itself [15]. Classical coagulation markers, prothrombin and activated thromboplastin time, and platelet count do not detect the procoagulant state [16].

Our data show that pulmonary embolism was usually diagnosed a few days after ICU admission. The incidence of pulmonary embolism was much higher in COVID-19 ARDS, as assessed through the

matching with non-COVID-19 patients (11.7 versus 2.1%). Another prospective cohort reported only 1.3% of PE in critically ill patients [17].

The mechanisms involved in thrombosis remain unclear. Endothelial inflammation was obvious, with very high levels of vWF:Ag and FVIII. Profound hypoxemia in the pulmonary capillaries may result in vasoconstriction reducing blood flow and promoting vascular occlusion [18]. Hypoxemia also induces activation of hypoxia-inducible factors (HIFs). HIFs are heterodimeric transcriptional factors consisting of HIF β subunit, expressed by all nucleated cells, and HIF1 α and HIF2 α subunits (for HIF1 and HIF2 respectively). Hypoxia induces HIF2 α subunits and decreases hydroxylation resulting in inducing or inhibition of many genes, including tissue factor (TF) and plasminogen-activator inhibitor-1 (PAI-1)[19, 20]. We did not measure PAI-1 in our patients, but we could assume that it would be very high, as it is shed by endothelial cells like vWF.

In a healthy lung, a fine balance exists between host coagulation and fibrinolytic pathways that controls fibrin deposition and their influence on the viability of the lung epithelium. It is well known that the urokinase plasminogen activator (uPA) bound to its receptor (uPAR) increases the efficiency of fibrinolysis on epithelial cell surfaces, clearing thereby abnormal fibrin deposits from the lung [21]. Impairment of this fibrinolytic function during lung inflammation results in abnormal accumulations of fibrin in alveolar spaces due to increase pro-coagulant activity [22]. Accordingly, data of bronchoalveolar lavage (BAL) fluid from patients with ARDS have revealed the presence of fibrin and increased levels of the uPA plasminogen activator inhibitor 1 (PAI-1) responsible for a decreased fibrinolytic activity within the alveolar space [23]. Increased PAI-1 levels were measured in the blood of SARS-CoV-infected patients during the 2002-2003 epidemic [24]. A reduced capacity to cleave and remove fibrin deposits corresponds with a poor clinical patient outcome as presence of exudates, composed of fibrin and proteinaceous material, blocks normal gas exchange [25].

Recently, Gralinsky et al. [26] using system biology and a severe acute respiratory syndrome coronavirus (SARS-CoV) model pathogen providing matched virologic, pathological, and transcriptomic data, concluded in a model of altered hemostatic balance defined by the expression of procoagulant and antifibrinolytic factors resulting in the induction of diffuse alveolar damage after infection. Therefore, we suggest that SARS-CoV infection overwhelms the normally protective, profibrinolytic pathway, including increased PAI-1 expression, contributing to severe ARDS.

Another factor that could contribute to thrombosis is the presence of a positive lupus anticoagulant (LA) that was detected in 50 patients out of the 57 tested (87.7%). We can reasonably exclude false positive LA due to the presence of heparin as most patients had <0.3 IU/mL and a heparin-neutralizing agent is contained in dRVV reagents, quenching heparin up to 0.8 anti-Xa IU/ml. LA are heterogeneous antibodies detected under various clinical circumstances where cellular damage due to infectious, autoimmune or inflammatory stimuli [27] leads to plasma membrane remodeling including the release of membrane microparticles and the exposure of phospholipids normally not accessible to the immune system. Resulting antibodies have been named anti-phospholipid antibodies (aPL). Strikingly, such LA/aPL elevations in a major proportion of COVID-19 patients have however rarely been observed with other pathologies, which probably reveals significant or massive cellular destruction. Of course, we cannot exclude that some patients were already positive for the LA before COVID-19 infection, since the frequency of non-symptomatic positive LA is higher in the ageing population [28].

Nevertheless, there is a strong association between high D-dimers, thrombosis and the presence of LA early in the COVID-19 course. Moreover, two patients had livedo reticularis and another one had IgM type anticardiolipin antibody at 48 MPL. In our cohort, 29 patients had acute renal failure (ARF) KDIGO3 requiring renal replacement therapy (19.3%) and many had less severe renal failure with proteinuria (data not shown). Renal failure is often present at admission, while hypotension is not. The mechanism of ARF is probably multifactorial. It may be an association of dehydration, vascular leakage, hypoxia and aPL-associated nephropathy. Evidence of thrombotic microangiopathy in our patients is difficult to evidence as renal biopsy was not performed. Systemic inflammation – essentially via IL-6 – may contribute to renal injury as observed during influenza A H1N1 [29] and ARDS [30]. ARF acts as an amplification loop [31]. Nevertheless, some patients were admitted with ARF while dehydration was clinically evident with aqueous diarrhea for few days prior to admission. Interestingly, these patients recover diuresis with hydration without improvement in ARF arguing for an intricate mechanism. Overhydration is a major concern during ARDS and high venous pressure (aggravated by high levels of PEEP) and venous congestion of the kidneys may also play a role in the development of ARF during ICU stay.

Some viruses are known to activate the coagulation cascade, mainly by promoting tissue factor on endothelial cells (HSV and Dengue virus) as well as on lymphoid macrophages and circulating blood cells (Ebola virus) [32]. Clinical manifestations with Dengue and Ebola viruses are disseminated intravascular coagulation with an hemorrhagic pattern [33]. Our patients with COVID-19 had no such phenotype but were highly thrombotic without evidence of DIC. Moreover, this phenotype is also different from that of patients admitted in ICU with ARDS due to bacterial pneumonia and might be a specific presentation of COVID-19.

Being observational, our study has some limitations. We have notably not been able to describe the pathophysiological hypothesis leading to the high incidence of clinically relevant thrombosis in COVID-19 patients, yet we have emitted some hypothesis based on clinical and biological considerations. As a large number of COVID-19 patients were still intubated at the time of data collection, the incidence of thrombotic complications is probably under-estimated. Finally, we did not have a systematic standardized assessment of thromboembolic events, and imaging was performed based on the evolution of clinical or laboratory parameters, which may have led to variations according to the treating physicians.

This study has established that despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 develop life-threatening thrombotic complications. The monitoring of anticoagulant treatment should be achieved through anti-Xa measurement, owing to changes of standard hemostasis parameters in this particular pathology. Although Tang et al. [3] suggested that anticoagulant therapy mainly with LMWH appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer, higher anticoagulation targets than usual should probably be taken into consideration.

Declarations:

Funding: NA

Conflicts of interest: The authors have no conflicts of interest to declare.

Ethics approval: The local ethics committee of the University Hospital of Strasbourg approved the study (reference CE-2020-34).

Availability of data and material: All available data are published in the current manuscript.

Authors' contributions: All authors whose names appear on the submission contributed substantially to the conception and design of the study, the acquisition of data, or the analysis and interpretation of the data.

Bibliography

1. Glass WG, Subbarao K, Murphy B, Murphy PM, (2004) Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. *Journal of immunology* 173: 4030-4039
2. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, Zhang C, Boyle C, Smith M, Phillips JP, (2020) Fair Allocation of Scarce Medical Resources in the Time of Covid-19. *The New England journal of medicine*
3. Tang N, Li D, Wang X, Sun Z, (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Journal of thrombosis and haemostasis* : JTH
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L, (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 395: 507-513
5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z, (2020) Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Jama*
6. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochweg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellingham GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP, (2017) *Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016*. *Intensive care medicine* 43: 304-377

7. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T, (2020) ISTH interim guidance on recognition and management of coagulopathy in COVID-19
8. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *Journal of thrombosis and haemostasis : JTH*. 2020. doi:10.1111/JTH.14817
9. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS, (2012) Acute respiratory distress syndrome: the Berlin Definition. *Jama* 307: 2526-2533
10. Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, Kitamura N, Saitoh D, (2016) Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. *Critical care* 20: 287
11. Taylor FB, Jr., Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis, (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. *Thrombosis and haemostasis* 86: 1327-1330
12. Delabranche X, Boisrame-Helms J, Asfar P, Berger A, Mootien Y, Lavigne T, Grunebaum L, Lanza F, Gachet C, Freyssinet JM, Toti F, Meziani F, (2013) Microparticles are new biomarkers of septic shock-induced disseminated intravascular coagulopathy. *Intensive care medicine* 39: 1695-1703
13. Delabranche X, Quenot JP, Lavigne T, Mercier E, Francois B, Severac F, Grunebaum L, Mehdi M, Zobairi F, Toti F, Meziani F, Boisrame-Helms J, on behalf to the Clinical Research in Intensive Care, Sepsis N, (2016) Early Detection of Disseminated Intravascular Coagulation During Septic Shock: A Multicenter Prospective Study. *Critical care medicine* 44: e930-939
14. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DeGroot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA, (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *Journal of thrombosis and haemostasis : JTH* 4: 295-306
15. Gershom ES, Sutherland MR, Lollar P, Prydzial EL, (2010) Involvement of the contact phase and intrinsic pathway in herpes simplex virus-initiated plasma coagulation. *Journal of thrombosis and haemostasis : JTH* 8: 1037-1043
16. Oudemans-van Straaten HM, (2015) Hemostasis and thrombosis in continuous renal replacement treatment. *Seminars in thrombosis and hemostasis* 41: 91-98
17. Lim W, Meade M, Lauzier F, Zarychanski R, Mehta S, Lamontagne F, Dodek P, McIntyre L, Hall R, Heels-Ansdell D, Fowler R, Pai M, Guyatt G, Crowther MA, Warkentin TE, Devereaux PJ, Walter SD, Muscedere J, Herridge M, Turgeon AF, Geerts W, Finfer S, Jacka M, Berwanger O, Ostermann M, Qushmaq I, Friedrich JO, Cook DJ, Investigators PRFtiCCT, (2015) Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. *Critical care medicine* 43: 401-410
18. Grimmer B, Kuebler WM, (2017) The endothelium in hypoxic pulmonary vasoconstriction. *J Appl Physiol* (1985) 123: 1635-1646
19. Yan SF, Mackman N, Kisiel W, Stern DM, Pinsky DJ, (1999) Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. *Arterioscler Thromb Vasc Biol* 19: 2029-2035
20. Gupta N, Zhao YY, Evans CE, (2019) The stimulation of thrombosis by hypoxia. *Thromb Res* 181: 77-83
21. Hattori N, Sisson TH, Xu Y, Desai TJ, Simon RH, (1999) Participation of urokinase-type plasminogen activator receptor in the clearance of fibrin from the lung. *Am J Physiol* 277: L573-579

22. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, Chapman HA, Jr., (1990) Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. *The New England journal of medicine* 322: 890-897
23. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS, (1989) Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. *J Clin Invest* 84: 695-705
24. Wu YP, Wei R, Liu ZH, Chen B, Lisman T, Ren DL, Han JJ, Xia ZL, Zhang FS, Xu WB, Preissner KT, de Groot PG, (2006) Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients. *Thromb Haemost* 96: 100-101
25. Hoste EA, Roosens CD, Bracke S, Decruyenaere JM, Benoit DD, Vandewoude KH, Colardyn FA, (2005) Acute effects of upright position on gas exchange in patients with acute respiratory distress syndrome. *J Intensive Care Med* 20: 43-49
26. Gralinski LE, Bankhead A, 3rd, Jeng S, Menachery VD, Proll S, Belisle SE, Matzke M, Webb-Robertson BJ, Luna ML, Shukla AK, Ferris MT, Bolles M, Chang J, Aicher L, Waters KM, Smith RD, Metz TO, Law GL, Katze MG, McWeeney S, Baric RS, (2013) Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. *mBio* 4
27. Giannakopoulos B, Krilis SA, (2013) The pathogenesis of the antiphospholipid syndrome. *The New England journal of medicine* 368: 1033-1044
28. Goldman-Mazur S, Wypasek E, Karpinski M, Stanisz A, Undas A, (2019) High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50years using the standardized protocol for thrombophilia screening. *Thromb Res* 176: 67-73
29. Bautista E, Arcos M, Jimenez-Alvarez L, Garcia-Sancho MC, Vazquez ME, Pena E, Higuera A, Ramirez G, Fernandez-Plata R, Cruz-Lagunas A, Garcia-Moreno SA, Urrea F, Ramirez R, Correa-Rotter R, Perez-Padilla JR, Zuniga J, (2013) Angiogenic and inflammatory markers in acute respiratory distress syndrome and renal injury associated to A/H1N1 virus infection. *Exp Mol Pathol* 94: 486-492
30. Seeley EJ, (2013) Updates in the management of acute lung injury: a focus on the overlap between AKI and ARDS. *Adv Chronic Kidney Dis* 20: 14-20
31. Malek M, Hassanshahi J, Fartootzadeh R, Azizi F, Shahidani S, (2018) Nephrogenic acute respiratory distress syndrome: A narrative review on pathophysiology and treatment. *Chin J Traumatol* 21: 4-10
32. Antoniak S, Mackman N, (2014) Multiple roles of the coagulation protease cascade during virus infection. *Blood* 123: 2605-2613
33. Basler CF, (2017) Molecular pathogenesis of viral hemorrhagic fever. *Semin Immunopathol* 39: 551-561

Figures:

Fig. 1: 66-year-old man at day 8 of ICU stay for ARDS secondary to Covid-19. CTPA demonstrating a proximal right pulmonary artery luminal defect and major bilateral alveolar consolidation




Fig. 2: Coagulation parameters of the matched COVID-19 ARDS (n=77 patients); and non-COVID-19 ARDS patients (n=145 patients); aPTT: activated partial thromboplastin time, PT: prothrombin time




Table 1: Characteristics of COVID-19 ARDS and non-COVID-19 ARDS

	Population before matching (n = 383)			Population after matching (n = 222)		
	Non-COVID-19 ARDS (n=233)	COVID-19 ARDS (n=150)	p	Non-COVID-19 ARDS (n=145)	COVID-19 ARDS (n=77)	p
Age – median, IQR	74 [63; 81]	63 [53; 71]	<0.001	72 [61; 80]	68 [61; 75]	0.593
Male - n (%)	164 (70.4)	122 (81.3)	0.02	112 (77.2)	63 (81.8)	0.426
Medical history - n (%)						
Malignancies/hemopathies	31 (13.4)	9 (6.0)	0.02	14 (9.7)	6 (7.8)	0.678
Cardiovascular diseases	143 (61.4)	72 (48.0)	0.01	85 (58.6)	42 (55.6)	0.753
Thrombo-embolic event	13 (5.6)	8 (5.3)	0.92	9 (6.2)	7 (9.1)	0.42
Cerebrovascular diseases	23 (10.0)	7 (4.7)	0.06	8 (5.5)	5 (6.5)	0.788
Immune diseases	13 (5.6)	4 (2.7)	0.17	7 (4.8)	4 (5.2)	0.951
Diabetes	51 (21.9)	30 (20.0)	0.66	29 (20.0)	17 (22.1)	0.589
Chronic liver disease	21 (9.0)	4 (2.7)	0.01	7 (4.8)	3 (3.9)	0.816
Chronic renal disease	38 (16.3)	6 (4.0)	<0.001	14 (9.7)	5 (6.5)	0.438
Respiratory disease	49 (21.2)	21 (14.0)	0.07	36 (24.8)	11 (14.3)	0.207
Baseline SAPS II – median, IQR	61 [49; 76]	49 [37; 64]	<0.001	54 [45; 69]	53 [46; 67]	0.560
Baseline SOFA – median, IQR	11 [9; 13]	8 [5; 10]	<0.001	10 [8; 13]	9 [7; 12]	0.204
PaO₂/FiO₂ on ICU admission (mmHg) – median, IQR	142 [93; 195]	125 [97; 170]	<0.02	118 [89; 174]	135 [99; 181]	0.520

Invasive mechanical ventilation - n (%)	233 (100)	150 (100)	1	145 (100)	77 (100)	1
Baseline heparin treatment – n (%)						
Prophylactic dosing*	188 (80.7)	105 (70.0)	0.27	110 (75.9)	60 (77.9)	0.768
Therapeutic dosing	45 (19.3)	45 (30.0)	0.02	35 (24.1)	17 (22.1)	0.697
ECMO – n (%)	10 (4.3)	12 (8.1)	0.124	7 (4.8)	4 (5.2)	0.952
ECMO duration (days) – median, IQR	8 [5.3; 10.8]	7 [4.3; 11.0]	0.642	10.0 [7.0; 11.5]	6.5 [4.5; 9.0]	0.527

SOFA: Sequential Organ Failure Assessment; SAPSII: simplified acute physiology score II

* Prophylactic dosing was 4000 UI/day for low molecular weight heparin or if contra-indicated, unfractionated heparin at 5-8 U/kg/hour.

Table 2: Coagulation parameters of COVID-19 patients

	All patients (n=150)
Baseline coagulation parameters	
Platelet count ($10^9/L$) – <i>normal range: 150-400.10⁹/L</i>	200 [152; 267]
aPTT – <i>normal range: 0.7-1.2</i>	1.2 [1.1; 1.3]
PT (%) – <i>normal range: >70%</i>	84 [73; 91]
INR – <i>normal range: 1.00-1.15</i>	1.12 [1.05; 1.25]
D-dimers (mg/L) – <i>normal range: <0.5 mg/L</i>	2.27 [1.16; 20.0]
Fibrinogen (g/L) – <i>normal range: 2-4 g/L</i>	6.99 [6.08; 7.73]
Antithrombin activity (%) – <i>normal range: 50-150%</i>	91 [78; 102]
Factor V (%) – <i>normal range: >70%</i>	136 [115; 150]
Factor VIII (%) – <i>normal range: 60-150%</i>	341 [258; 416]
vWF activity (%)	328 [212; 342]
vWF antigen (%) – <i>normal range: 50-150%</i>	455 [350; 521]
Lupus anticoagulant* – n (%):	50/57 (87.7)
Screen patient (s)	68.6 [59.5; 85.4]
Screen ratio – <i>normal range: <1.20</i>	1.63 [1.43; 2.04]
Confirm patient (s)	43.9 [40.9; 48.4]
Confirm ratio – <i>normal range: <1.20</i>	1.25 [1.13; 1.46]
Screen/Confirm ratio – <i>normal range: <1.20</i>	1.40 [1.25; 1.48]

aPTT: activated partial thromboplastin time; INR: International Normalized Ratio; PT: prothrombin time; vWF: von Willebrand factor.

All results are given in median [IQR], except if specified otherwise.

* Measured during ICU stay.

Table 3: Outcomes of COVID-19 ARDS and non-COVID-19 ARDS

	Population before matching (n = 383)				Population after matching (n = 222)			
	Non-COVID-19-ARDS (n = 233)	COVID-19-ARDS (n = 150)	OR [95% IC]	p	Non-COVID-19-ARDS (n = 145)	COVID-19-ARDS (n = 77)	OR [95% IC]	p
Thrombo-embolic complications - n (%)	14 (6.0)	27 (18.0)	3.4 [1.7 – 7.3]	<0.001	7 (4.8)	9 (11.7)	2.6 [1.1 – 6.1]	0.04
Pulmonary embolisms – n (%)	3 (1.3)	25 (16.7)	15.2 [4.5 – 80.4]	<0.001	3 (2.1)	9 (11.7)	6.2 [1.6 – 23.4]	0.01
Deep vein thrombosis - n (%)	3 (1.3)	3 (2.0)	1.0 [0.1 – 9.2]	1	2 (1.4)	0 (0.0)	/	/
Myocardial infarction - n (%)	6 (2.6)	0 (0.0)	0.0 [0.0 – 1.3]	0.09	2 (1.4)	0 (0.0)	/	/
Cerebral ischemic attack - n (%)	1 (0.4)	2 (1.3)	3.1 [0.2– 185.5]	0.68	0 (0.0)	0 (0.0)	/	/
Limb ischemia - n (%)	0 (0.0)	1 (0.7)	Inf [0.0 – Inf]	0.78	0 (0.0)	0 (0.0)	/	/
Mesenteric ischemia - n (%)	3 (1.3)	1 (0.7)	0.5 [0.0 – 6.5]	0.98	2 (1.4)	1 (1.30)	0.96 [0.09 – 9.8]	0.97
Nb of RRT filter per dialyzed patient – median, IQR	1.0 [2.0 – 1.0]	3.0 [2.0 – 7.0]	/	<0.001	2.0 [1.0 – 2.5]	3.0 [2.0 – 6.0]	/	0.03
Nb of RRT filter per day of RRT – median, IQR	0.3 [0.3; 0.5]	0.7 [0.5; 1.0]	/	<0.001	0.3 [0.3; 0.4]	0.7 [0.5; 1.0]	/	<0.001
ECMO oxygenator thrombosis - n (%)	1/10 (10.0)	2/12 (16.7)	/	0.59	1/7 (14.3)	0/4 (0.0)	/	/
Hemorrhagic complications - n (%)	1 (1.8)	4 (2.7)	2.4 [0.27 - 28.5]	0.60	2 (1.4)	0 (0.0)	/	/

ARDS: acute respiratory distress syndrome; ECMO: extracorporeal membrane oxygenation; RRT: renal replacement therapy

Supplementary material

Methods

Blood samples and platelet-poor plasma preparation

Blood samples were collected in 0.109 M sodium citrate tubes.

Prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer and von Willebrand factor antigen were determined in plasma immediately after a single centrifugation (2500 g for 10 min).

Regarding factor VIII activity and lupus anticoagulant detection, platelet-poor plasma (PPP) was obtained by double centrifugation (2 x 2500 g for 10 min). PPP was frozen at -80°C until use. PPP was thawed for 4 min in a 37°C water bath before the assays.

Laboratory analysers

All haemostasis assays were analysed on STA-R® Evolution (Diagnostica Stago®, Asnières-sur-Seine, France), except vWF activity, made on CS-2100i (Sysmex, Kobe, Japan), with standard commercial reagents.

Prothrombin time (PT)

PT was measured with the STA®-NeoPTimal reagent (Stago, Asnières-sur-Seine, France).

Activated partial thromboplastin time (APTT)

APTT was measured with the STA®-PPT A reagent (Stago).

Fibrinogen

Quantitative determination of fibrinogen level was made with the clotting method of Clauss, using the STA®-Liquid Fib reagent (Stago).

Factor V (FV) activity

FVIII activity was measured with the one-stage clotting assay (OSA) using STA®-Néoplastine CI and STA®-Deficient V reagents (Stago), calibrated to normal human plasma.

Factor VIII (FVIII) activity

FVIII activity was measured with a one-stage clotting assay (OSA) using STA®-C.K. Prest and STA®-Immunodef VIII reagents (Stago), calibrated to normal human plasma.

Von Willebrand factor antigen (vWF:Ag)

vWF:Ag was quantified by immunoturbidimetry using Liatest® vWF:Ag reagent (Stago).

Von Willebrand factor activity (vWF:Rco)

vWF activity was a ristocetin cofactor activity quantified by turbidimetry using BC von Willebrand® reagent (Siemens, Marburg, Germany).

Antithrombin activity

Antithrombin activity was measured with a chromogenic substrate assay using STA®-Stachrom AT III reagent (Stago)

D-dimer

D-dimer was quantified by immunoturbidimetry using Liatest® D-Di PLUS reagent (Stago).

Lupus anticoagulant (LA) detection

Lupus anticoagulant (LA) detection was based on several tests.

First, two screening tests were performed, respectively a Diluted Russel Viper Venom Time (dRVVT screen) made with the STA®-Stacloct dRVV Screen reagent (Stago), and a LA sensitive APPT performed with the STA®-PPT LA reagent (Stago).

Positivity of one or both screening tests induced a mixing test at 1:1 proportion with a commercial frozen PNP (Cryocheck™ Pooled Normal Plasma, Cryocheck, Montpellier, France). Moreover, a positive dRVVT screen induced a confirmatory test with an increased concentration of phospholipids (dRVVT confirm), performed with the STA®-Staclot dRVV Confirm reagent (Stago).

dRVVT screen, DRVVT confirm and APTT results were expressed as a ratio of patient-to-PNP. Mixing tests results were expressed as an index of circulating anticoagulant (ICA). LA was considered as positive only if the normalized dRVVT ratio (screen ratio/confirm ratio) was > 1.2 and all causes of false positive were excluded (i.e. anticoagulation conditions).